MRNA: financial statements from SEC — TradeAlmanac

MRNA

Moderna, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31 Dec 2025	31 Dec 2024
Revenue	1.94B	3.24B
Cost of revenue	868M	1.46B
Research and development	3.13B	4.54B
Selling, general and administrative	1.02B	1.17B
Operating expenses	5.02B	7.18B
Operating income	−3.07B	−3.95B
Pre-tax income	−2.77B	−3.61B
Income tax	54M	−46M
Net income	−2.82B	−3.56B
Earnings per share	−7.26	−9.28
Earnings per share, diluted	−7.26	−9.28
Weighted average shares	389M	384M
Weighted average shares, diluted	389M	384M

Balance sheet

Metric	31 Mar 2026	31 Dec 2025	30 Sept 2025	30 Jun 2025	31 Mar 2025	31 Dec 2024	30 Sept 2024	30 Jun 2024
Cash and equivalents	1.91B	2.60B	1.13B	1.28B	1.62B	1.93B	1.64B	2.48B
Receivables	71M	184M	1.05B

Cash flow

Metric	31 Dec 2025	31 Dec 2024
Operating cash flow	−1.87B	−3.00B
Share-based compensation	483M	429M
Capital expenditure	192M	1.05B
Investing cash flow	1.95B	1.95B
Share buybacks	2M	0
Financing cash flow	593M	56M

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator